TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Bronchiectasis
Brief Summary: The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Bronchiectasis (Brx) and if so how it compares to placebo (a substance which does not have any action).


Options:
A: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Mannitol; Type: EXPERIMENTAL; Interventions: Drug: Inhaled mannitol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched control | Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): Mannitol | Intervention Type: DRUG; Name: Matched control; Assigned to Arm(s): Control
C: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin, Placebo
D: Arm Label: AZD9668 active treatment; Type: EXPERIMENTAL; Interventions: Drug: AZD9668 | Arm Label: AZD9668 placebo treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): AZD9668 active treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AZD9668 placebo treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled Study on Short-term Psychotherapy After Acute Myocardial Infarction: The Step-in-AMI Trial (Short TErm Psychotherapy IN Acute Myocardial Infarction)
Brief Summary: Psychosocial factors play an important role in the pathophysiology of acute myocardial infarction (AMI), but it is not known if psychotherapy is beneficial after the contemporary treatment of AMI consisting of medical and interventional therapy.

The investigators have designed a randomized, controlled study to assess the effects of short-term psychotherapy (STP) on the clinical outcomes of patients who have undergone an emergency percutaneous coronary intervention (PCI) post-AMI.


Options:
A: Arm Label: Cognitive behavioral therapy (CBT); Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Arm Label: Educational session and treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational session and treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): Cognitive behavioral therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Educational session and treatment as usual; Assigned to Arm(s): Educational session and treatment as usual
B: Arm Label: Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical therapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): Psychotherapy | Intervention Type: DRUG; Name: Medical therapy; Assigned to Arm(s): Control
C: Intervention Type: BEHAVIORAL; Name: multifactorial continued educational - behavioural programme; Assigned to Arm(s): N/A
D: Arm Label: ACT-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACT-based intervention, Behavioral: usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: ACT-based intervention; Assigned to Arm(s): ACT-based intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): ACT-based intervention, Usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled Study on Short-term Psychotherapy After Acute Myocardial Infarction: The Step-in-AMI Trial (Short TErm Psychotherapy IN Acute Myocardial Infarction)
Brief Summary: Psychosocial factors play an important role in the pathophysiology of acute myocardial infarction (AMI), but it is not known if psychotherapy is beneficial after the contemporary treatment of AMI consisting of medical and interventional therapy.

The investigators have designed a randomized, controlled study to assess the effects of short-term psychotherapy (STP) on the clinical outcomes of patients who have undergone an emergency percutaneous coronary intervention (PCI) post-AMI.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Aerobic Exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Pill. | Intervention Type: BEHAVIORAL; Name: Supervised Aerobic Exercise; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Pill.; Assigned to Arm(s): 3
B: Arm Label: Referred Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy, Drug: Sertraline, citalopram, or bupropion | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): Stepped Care | Intervention Type: DRUG; Name: Sertraline, citalopram, or bupropion; Assigned to Arm(s): Stepped Care | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Referred Care
C: Arm Label: Sertraline/omega-3 supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline/omega-3 | Arm Label: Sertraline/corn oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline/Corn Oil | Intervention Type: DRUG; Name: Sertraline/omega-3; Assigned to Arm(s): Sertraline/omega-3 supplement | Intervention Type: DRUG; Name: Sertraline/Corn Oil; Assigned to Arm(s): Sertraline/corn oil
D: Arm Label: Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical therapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): Psychotherapy | Intervention Type: DRUG; Name: Medical therapy; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cerebral Autoregulation Monitoring in Adults Undergoing Cardiac Surgery: Comparison of Near Infrared Spectroscopy With Transcranial Doppler
Brief Summary: Blood flow to the brain is normally regulated to ensure a constant supply of blood with oxygen and nutrients. During heart surgery using cardiopulmonary bypass, blood pressure is kept at a level that may or may not be below an individual's lower level of brain blood flow autoregulation. If lower, the brain may be exposed to an inadequate blood flow that could result in brain damage. The purpose of this study is to examine whether monitoring with a non-invasive FDA approved device that measures oxygen saturation of the superficial layers of the brain (near infrared spectroscopy) can, when combined with blood pressure measurements, provide information on the blood pressure level where brain blood flow is not autoregulated. The goal of this research is to develop a method to individualize blood pressure during surgery to a level that is within a patient's brain blood flow autoregulation range as a means for improving outcomes for patient undergoing heart surgery.


Options:
A: Arm Label: Embol-X Embolic Protection Device; Type: ACTIVE_COMPARATOR; Interventions: Device: Embol-X Embolic Protection Device | Arm Label: CardioGard Cannula; Type: ACTIVE_COMPARATOR; Interventions: Device: CardioGard Cannula | Arm Label: Standard Cannula; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Embol-X Embolic Protection Device; Assigned to Arm(s): Embol-X Embolic Protection Device | Intervention Type: DEVICE; Name: CardioGard Cannula; Assigned to Arm(s): CardioGard Cannula
B: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group A; Type: N/A; Interventions: N/A
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing
Brief Summary: The study will assess the hypothesis that the combination warfarin \& clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding complications while equally safe with respect to the prevention of thrombotic complications in patients with both indications for warfarin use and dual antiplatelet (clopidogrel 75mg/day + aspirin 80mg/day) treatment.


Options:
A: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
B: Arm Label: dabigatran etexilate 110 or 150 mg; Type: EXPERIMENTAL; Interventions: Drug: optional ASA as comedication, Drug: placebo to ASA, Drug: dabigatran etexilate | Arm Label: ASA 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo to optional ASA as comedication, Drug: placebo to dabigatran etexilate, Drug: ASA 100 mg | Intervention Type: DRUG; Name: optional ASA as comedication; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to ASA; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to optional ASA as comedication; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: placebo to dabigatran etexilate; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: ASA 100 mg; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg
C: Arm Label: Monotherapy group; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel | Arm Label: DAPT group; Type: EXPERIMENTAL; Interventions: Drug: aspirin, Drug: clopidogrel, Drug: cilostazol | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): DAPT group, Monotherapy group | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): DAPT group, Monotherapy group | Intervention Type: DRUG; Name: cilostazol; Assigned to Arm(s): DAPT group
D: Arm Label: Aspirin + clopidogrel + oral anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Arm Label: Oral anticoagulants + clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Intervention Type: DEVICE; Name: PCI (percutaneous coronary intervention); Assigned to Arm(s): Aspirin + clopidogrel + oral anticoagulation, Oral anticoagulants + clopidogrel

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia
Brief Summary: The purpose of this study is to investigate and evaluate the efficacy of Eszopiclone in Japanese participants with primary insomnia.


Options:
A: Arm Label: Eszopiclone 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 1 mg | Arm Label: Eszopiclone 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 2 mg | Arm Label: Eszopiclone 3 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 3 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Zolpidem Tartrate 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem Tartrate 10 mg | Intervention Type: DRUG; Name: Eszopiclone 1 mg; Assigned to Arm(s): Eszopiclone 1 mg | Intervention Type: DRUG; Name: Eszopiclone 2 mg; Assigned to Arm(s): Eszopiclone 2 mg | Intervention Type: DRUG; Name: Eszopiclone 3 mg; Assigned to Arm(s): Eszopiclone 3 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Zolpidem Tartrate 10 mg; Assigned to Arm(s): Zolpidem Tartrate 10 mg
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy
Brief Summary: This is a double blind, multicentre, randomized, placebo-controlled study. The eligible patients will be randomized to receive gefitinib or placebo at 1:1 ratio. This study will recruit 296 male or female, histologically or cytologically diagnosed locally advanced or metastatic NSCLC patients with a World Health Organization (WHO) Performance Status (PS) 0-2. Patients must have completed 4 cycles of platinum based first line doublet chemotherapy without experiencing disease progression or unacceptable toxicity. The chemotherapy shall be given every 3 weeks, which includes cisplatin or carboplatin, combined with any one of the following: gemcitabine, paclitaxel, docetaxel, vinorelbine.


Options:
A: Arm Label: Paclitaxel/Carboplatin/Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel/Carboplatin/Gefitinib | Arm Label: Paclitaxel/Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel/Carboplatin | Intervention Type: DRUG; Name: Paclitaxel/Carboplatin/Gefitinib; Assigned to Arm(s): Paclitaxel/Carboplatin/Gefitinib | Intervention Type: DRUG; Name: Paclitaxel/Carboplatin; Assigned to Arm(s): Paclitaxel/Carboplatin
B: Arm Label: gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Icotinib; Type: EXPERIMENTAL; Interventions: Drug: Icotinib | Arm Label: Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Icotinib; Assigned to Arm(s): Icotinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Gefitinib
D: Arm Label: Alimta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed (Alimta) | Arm Label: IRESSA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib (IRESSA) | Intervention Type: DRUG; Name: Pemetrexed (Alimta); Assigned to Arm(s): Alimta | Intervention Type: DRUG; Name: Gefitinib (IRESSA); Assigned to Arm(s): IRESSA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness
Brief Summary: Randomized clinical trial to evaluate a flexibly-dosed-3-medication combination for up to 6 months in smokers with medical illness


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2
B: Arm Label: Bupropion and Weight Concerns intervention; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: weight concerns intervention | Arm Label: Placebo and Weight Concerns; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: weight concerns intervention | Arm Label: Bupropion and standard smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: smoking cessation intervention | Arm Label: Placebo and standard smoking cessation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: smoking cessation intervention | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Bupropion and standard smoking cessation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Weight Concerns, Placebo and standard smoking cessation | Intervention Type: BEHAVIORAL; Name: weight concerns intervention; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Placebo and Weight Concerns | Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): Bupropion and standard smoking cessation, Placebo and standard smoking cessation
C: Arm Label: Smoking counseling, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking counseling, Drug: placebo | Arm Label: Smoking counseling, Varenicline; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking counseling, Drug: varenicline | Intervention Type: BEHAVIORAL; Name: Smoking counseling; Assigned to Arm(s): Smoking counseling, Placebo, Smoking counseling, Varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Smoking counseling, Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Smoking counseling, Placebo
D: Arm Label: Bupropion SR; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: smoking cessation counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Behavioral: smoking cessation counseling | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: smoking cessation counseling; Assigned to Arm(s): Bupropion SR, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness
Brief Summary: Randomized clinical trial to evaluate a flexibly-dosed-3-medication combination for up to 6 months in smokers with medical illness


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness
Brief Summary: Randomized clinical trial to evaluate a flexibly-dosed-3-medication combination for up to 6 months in smokers with medical illness


Options:
A: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2
C: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
D: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Weekly Motivational Emails | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Weekly Motivational Emails | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Weekly Motivational Emails; Assigned to Arm(s): Bupropion, Varenicline

Answer: B